A RANDOMIZED, MASKED, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究的目的是： 1.比较标准剂量的重组人促红细胞生成素(RHuEPO)和安慰剂/假手术剂量，评价达贝泊丁对早产儿网织红细胞计数、红细胞压积、红细胞生成素浓度和输血需求的影响。 2.评估接受达贝泊丁治疗的18至22个月婴儿的神经发育结果，并与标准rHuEPO剂量和安慰剂/假剂量进行比较，并将神经发育结果与促红细胞生成素浓度相关联。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is: 1. To evaluate the effect of darbepoetin on reticulocyte count, hematocrits, erythropoietin concentrations, and transfusion requirements in premature infants, compared to standard rHuEpo dosing and compared to placebo/sham dosing. 2. To evaluate the neurodevelopmental outcome of infants at age 18 to 22 months receiving darbepoetin compared to standard rHuEpo dosing and compared to placebo/sham dosing, and correlate neurodevelopmental outcomes with erythropoietin concentrations.